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Abstract: Human adenoviruses are frequent cause of slight self-limiting infections in immune competent subjects, while causing
life-threatening  and  disseminated  diseases  in  immunocompromised  patients,  particularly  in  the  subjects  affected  by  acquired
immunodeficiency syndrome and in bone marrow and organ transplant recipients. Here, infections interest lungs, liver, encephalon,
heart, kidney and gastro enteric tract. To date, human adenoviruses comprise 51 serotypes grouped into seven species, among which
species C especially possesses the capability to persist in infected tissues. From numerous works, it emerges that in the recipient,
because of loss of immune-competence, both primary infection, via the graft or from the environment, and reactivated endogenous
viruses can be responsible for transplantation related adenovirus disease. The transplants management should include the evaluation
of  anti-adenovirus  pre-transplant  screening  similar  to  that  concerning  cytomegalovirus.  The  serological  screening  on
cytomegalovirus  immunity  is  currently  performed  to  prevent  viral  reactivation  from  grafts  and  recipient,  the  viral  spread  and
dissemination to different organs and apparatus, and potentially lethal outcome.
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INTRODUCTION
Human adenovirus (HAdV) infections, frequent in children since they are naïve hosts, are common in all age groups
of the population, and are generally asymptomatic or slight self-limiting in the immune competent subjects, where they
present  variable  symptomatology  and  different  localizations,  i.e.,  ocular,  cardiac,  respiratory  and  gastro-intestinal.
Despite their usual weak pathogenicity, HAdVs can cause severe affections, requiring hospitalization, such as acute
respiratory  diseases  (ARDs)  and  intestinal  lymphoid  hyperplasia  up  to  intussusception.  In  immunocompromised
patients,  particularly  in  the  subjects  suffering  from acquired  immunodeficiency  syndrome (AIDS)  and  in  allogenic
hematopoietic  stem  cells  (HSC)  and  solid  organ  transplant  recipients,  HAdV  often  cause  life-threatening  and
disseminated  infections,  named  transplantation  related  adenovirus  disease  [1].  In  these  subjects,  adenoviruses  are
responsible  for  a  broad  range  of  evident  infections,  affecting  bloodstream,  lungs,  liver,  encephalon,  heart,  kidney,
bladder and gastro enteric tract, singly or together.
To date, 51 distinct HAdV serotypes and numerous “types” are identified and grouped within seven species (A-G)
defined through genomic criteria. Specific anti-adenovirus neutralizing antibodies recognize single species, while those
recognizing the exon protein capsid are common to all  species [2]. Different adenoviral serotypes possess different
biological  and  pathogenetic  properties,  such  as  the  oncogenic  potential,  detectable  on  in  vitro  and  in  vivo  rodent’s
models, the spectrum of virus-host interactions and associated diseases. Since 1958, human adenoviruses are known to
establish  persistent  and  latent  infections,  both  in  lymphatic  tissue  and  in  solid  organs,  like  kidney  and  liver  [3].
Adenoviruses  belonging  to  species  C  (adenovirus  type  1,  2,  5,  6)  are  the  most  ascertained  to  remain  in  infected
organisms and the most commonly encountered in affected patients, especially in children under five. It is likely that the
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various features and presentations of HAdV, which depend on the infecting serotype, would occur both in immune-
competent and in immunocompromised hosts [4, 5].
In the last thirty years, the number of transplanted subjects and people suffering from AIDS enormously increased
and so the importance of HAdV and other latent viruses. Among these, the most relevant are those belonging to herpes
family, i.e., Cytomegalovirus (CMV), Epstein-Barr (EBV), Herpes Simplex (HSV), Human Herpesvirus 6 (HHV6) and
Varicella-Zoster (VZV) viruses [1]. Nevertheless, the pre-transplant protocols, which include the serological screening
in donors and recipients for all Herpes viruses, do not include that for Human Adenoviruses.
Many investigations on transplantation related adenovirus disease have looked at several clinical variables, such as
age of  recipient  and donor,  kind of  transplant,  i.e.,  bone marrow or  solid  organs,  preparatory regimen and primary
disease, to summarize the common characteristics of the infection. Nowadays, it is known that the rate of adenovirus
infection, the severity of disease and the incidence of mortality broadly vary, mostly depending on age of patients and
kind of graft. The highest prevalence is in fact among the pediatric population transplanted with hematopoietic stem
cells,  while  the  lowest  one  is  among  adults  transplanted  with  solid  organs.  In  this  second  cluster  of  patients,  the
adenoviral infection usually occurs in the graft, often leading to transplant failure and organ loss [5 - 7].
However, as effectively asserted by Chakrabarti, not enough is understood regarding the specific contribution of
primary infection, which can take place via the graft or environment, and the precise contribution of the reactivation of
endogenous viruses [8 - 10]. For this reason, specific strategies to provide a correct prevention are quite missing.
KNOWLEDGE ON CMV DISEASE TRANSPLANT RELATED, AND MANAGEMENT
As previously mentioned, serological assays towards the Herpes virus family is included in pre-transplant protocols,
and the relative data became more and more numerous and useful over time. Particularly, those results concerning the
cytomegalovirus serostatus, collected in homogenous groups of patients, allowed to achieve a deep knowledge of the
different pathways of CMV disease. The consequent preventive strategies have had a significant impact in reducing
mortality over the past two decades. Another example of usefulness of serology preventive emerges from the results
about EBV. The relative data, in fact,  led to the discovery of the Epstein-Barr virus-associated post-transplantation
lymphoproliferative disease and to the awareness of the risk associated with the transplantation procedure [9, 11].
In  2010,  thanks  to  the  analysis  of  CMV  serostatus,  George  and  colleagues  stated  that  the  highest  risk  of
cytomegalovirus  infection  in  adults  was  due  to  hematopoietic  stem cell  transplantation  (SCT)  whose  recipient  was
positive. The lowest risk was related to CMV naïve condition of both donor and recipient, and the intermediate one was
related  to  the  negative  recipient,  even  in  the  case  of  positive  donor  [12].  These  finding  highlighted  the  negligible
importance of primary infections and the dramatic role of endogenous reactivations in adults for the onset of CMV
infections related to stem cells transplant.
Kulberg-Lindh and colleagues, to study in children the viral opportunistic infections SCT related, retrospectively
analyzed  serum  samples  by  quantitative  Real-time  polymerase  chain  reaction  (RT-PCR)  detection  of  CMV,  EBV,
HHV6 and HAdV DNA during the first 6-12 months after the transplant, investigated the specific serostatus prior to
transplant  and clinical  variables.  Data  on DNAemia,  which occurs  in  47% for  CMV, in  45% for  EBV, in  28% for
HHV6  and  in  28%  for  HAdV,  and  increased  to  high  levels  in  the  three  lethal  infectious  outcomes,  allowed
distinguishing significant infections. The serum positivity for CMV immunoglobulin G in either recipient or donor,
other than the total body irradiation procedure and the anti-thymocyte globulin conditioning, indicated those patients
who needed to be closely followed and treated with preventive therapy [13]. Hiwarkar and colleagues, analyzing the
impact of viral reactivation in pediatric SCT recipients, reported that CMV and HAdV reactivation was the major risk
factor  for  mortality  following  transplant  [14].  However,  the  authors  considered  the  pre-transplant  CMV  and  EBV
seropositivity in donors and recipients as the first choice of investigation. On the contrary, they assessed the presence of
adenoviruses through the use of RT-PCR assay on recipient’s naso-pharyngeal aspirate and stool. The evaluation of
HAdV presence was thus restricted to pre-existing viruses from very recent or acute phases of infection, in a few tracts
of organism and only in recipients, wasting any detection of adenovirus during latency, in any tract of body and in
donors.
KNOWLEDGE  ON  TRANSPLANTATION  RELATED  ADENOVIRUS  DISEASE,  MANAGEMENT  AND
LIMITS
Currently,  the  pre-hematopoietic  cell  transplant  protocol  does  not  include  the  evaluation  of  anti-adenovirus
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serostatus, since it is considered not useful because of the existence of many different serotypes and because of the little
knowledge about the diagnostic efficiency of cross-reactive immunity. On the other hand, the authors of protocol affirm
that cellular immune responses, cross-reactive across various serotypes, likely provide a long-term protection against
the adenoviral reactivation and make serious adenovirus infections in adults uncommon [15]. These considerations led
to  a  stratification  of  the  risk  of  adenoviral  disease  that  only  concerns  a  generic  evaluation  of  kind  of  graft  and
preparatory regimen, and that misses the possibility to discover subjects at specific risk of HAdV reactivation.
The management of HAdV infections related to SCT currently implies great efforts and very high coasts to monitor
HAdV viremia early after transplant, like suggested in the scheme by Sive and colleagues. The scheme proposes weekly
PCR on blood, and stools or nasopharyngeal samples in the case of symptoms, until day 100 [16]. This protocol is not a
definitive strategy against HAdV infection, but is actually useful to early detect the disease, allowing both preventive
treatment and immediate therapy, possibly preventing disease severity. The protocol fits as well with the routine weekly
PCR screening for CMV and EBV [17].
Nevertheless,  it  is  evident  that  the  use  of  RT-PCR,  nowadays  the  most  suitable  molecular  technique  for  early
monitoring of viral presence, can just allow the tailoring of immune-suppression [6, 18]. Unlike the treatment for CMV,
no established therapy against adenovirus infections does exist and the therapeutic options are currently not satisfying.
In fact, the clearance of HAdV and a definitive cure require adequate immune reconstitution after HSCT, despite the
preemptive and therapeutic treatment with Cidofovir, characterized by relevant toxicity [6, 8, 19].
In 2011, Veltrop-Duits and colleagues evaluated the pre-existing HAdV serostatus in children recipients, to predict
viral  reactivations after hematopoietic SCT, and the presence of viral  DNA in graft  material,  measured by PCR, to
investigate as well the possible HAdV transmission from donor to recipient [20]. High pre-transplant titers of serotype
specific  neutralizing  antibodies  against  HAdV  appeared  to  predispose  to  infections  with  the  same  serotype  after
transplant, instead of protecting from it. These results, explainable by the decreased or disappeared immunity due to the
preparatory regimen, contradict the statements in the pre-hematopoietic cell transplant protocol [15] about the long-term
protection against HAdV reactivation. These data also suggest that reactivated endogenous viruses rather than primary
infections would be the major pathway of adenoviral infection, like mentioned for CMV disease in the work by George
[12].  A  significant  risk  for  adenoviral  reactivation  and  dissemination  also  emerged  from  data  about  HAdV  DNA
presence,  detected prior  to  SCT in  feces  or  nasopharyngeal  aspirates  of  pediatric  recipients  [18,  21].  In  a  previous
investigation, instead, positive donor’s serostatus appeared as very important risk for HAdV infection in recipients, thus
suggesting the contagious with the graft [22].
Discrepancies between different studies show how complex the problem of transplant related adenovirus infection
and the need to get more information. Moreover, in the opinion of Sive and other authors, also the true incidence and
the clinical significance of HAdV DNA presence in the blood, as well as the viremic titer, remain unclear because of the
wide variation in the study populations and in the methodology [16, 23].
Clinicians  usually  perform serological  tests  to  obtain  indirect  diagnosis  of  viral  infections,  but  the  presence  of
specific antibodies is especially the evidence of specific protection against acute self-limiting viral infections, such as
flu and hepatitis A. Among cohorts of people where immune-competence does persist, such as children affected by
cystic fibrosis and military recruits, they turned out to be protected against HAdV infection by the presence of specific
neutralizing antibodies [20]. Data on serostatus are of scarce utility if the antibodies production gets weak, such as after
transplant when the frequent use of blood transfusions and intravenous immunoglobulin also limit the significance [13].
Differently, when performed prior to transplant, the seropositivity towards persistent and latent viruses should represent
evidence for their possible presence and for possible reactivation, which could occur after immunosuppression.
INTERPRETATION OF ANTI-CMV SEROLOGICAL ASSAY AND CLINICAL USE
As already mentioned, several authors consider HAdV serostatus of recipients and donors of limited value because
most  individuals  was  in  contact  with  one  or  more  serotypes,  while  diagnostic  tests  usually  detect  generic  HAdV
antibodies, not type-specific [15, 20, 22, 24]. At the same, however, the immunological plurality of viral strains could
also diminish the utility of serological screening for the transplant related CMV disease. In fact, the cytomegalovirus
serostatus is commonly valuated with commercial enzyme-linked immunosorbent assay (ELISA) kits, which use entire
CMV-infected cells  as  antigens and do not  allow distinguishing between antibodies against  different  strains.  A not
routine, strain-specific seroepidemiology towards the conserved CMV antigen domain 2 (AD2) epitope of glycoprotein
B (gB) and towards the not conserved glycoprotein H (gH) allowed observing the protection from CMV reinfection in
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renal transplant in patients CMV-gH antibody matched, but not in those CMV-gH antibodies mismatched [25]. The
mismatching  of  gH  serotypes  was  associated  with  CMV  disease  after  renal  transplantation  and  with  low  level  of
neutralizing antibodies against gB AD2. This finding described the strain-dependent immune responses, the consequent
absence of protection towards different CMV strains and explained the why of viral transmission during pregnancy in
mothers routinely CMV seropositive [26, 27]. The strain-specific analysis, performable at the aim of epidemiologic
investigations, makes possible to recognize the relevant burden of reactivation and reinfection in the pathogenesis of
transplant related CMV disease. Nevertheless, the simple routine serological screening, despite its limit, is currently
performed in patients prior to transplant, resulting in the basic discovery of risk for CMV reactivation.
INTERPRETATION OF ANTI-HADV SEROLOGICAL ASSAY AND LIMITS OF CLINICAL USE
Nowadays, the genomic investigations replace the neutralization assays in the definition of HAdV types and are
performed  in  the  contest  of  epidemic  infectious  events  or  specific  investigations  [28].  The  serological  typing
characterization  of  adenovirus  is  still  useful  for  detecting  type-specific  neutralizing  anti-HAdV  antibodies.  These
assays, although represent a diagnostic effort, could be at least addressed to discovery species C, which most frequently
shows the biological behavior of latency, to evaluate the dynamics of viral diffusion and to clarify basic pathogenic
aspects.  However,  more  important  and  feasible,  any  data  obtained  from  the  performance  of  routine  cross-reacting
antibodies assay should be hopeful to recognize the recipients at risk for endogenous reactivation.
As already highlighted, the persistent lack of effective therapies against HAdV makes the reconstitution of antiviral
immunity of paramount importance, leading to the need of adoptive therapy. Specific cytotoxic lymphocytes can be
utilized as a passive immunization for prophylaxis in high-risk allogenic hematopoietic SCT and solid organ recipients,
and for the treatment in the case of infection, when any necessity would be in advance recognized. In fact, even if the
new generation of virus-specific lymphocytes has increased the feasibility of their use, this therapy remains demanding
in  terms  of  cost  and  time  [29,  30].  Moreover,  it  was  also  demonstrated  that  human  CD4+  T  cells  stimulated  by
conserved adenovirus hexon peptides from a single species recognize cells infected with HAdV serotypes belonging to
different one [31]. The cross-reactivity, while for the gene therapy may limit the utility of switching to HAdV-based
vectors derived from not common adenoviral serotypes, instead may benefits the utilization of HAdV-specific T cells in
transplant recipients and makes the early individuation of recipients at risk, and a careful evaluation of any reciprocal
donor-recipient serostatus, necessary. Since the generation of antigen-specific T cells from naïve T cell donors is still
difficult, laborious and time-consuming, allogeneic third party T-cell donors offers an alternative option for recipients
with virus seronegative donors or receiving cord blood in HSCT and cadaveric graft in SO transplantation [32]. The
efficient  treatment  of  high-risk  patients  requires  the  rapid  recruitment  of  suitable  T-cell  donors,  selected  from  the
allogeneic cell registry alloCELL (www.alloCELL.org) established at Hannover Medical School (MHH). Here, donor
seropositivity  provides  an  opportunity  to  transfer  virus-specific  lymphocytes  to  mediate  immune  protection  in  the
immunosuppressed recipient. In this context, a recent work evaluated CMV-, EBV- and ADV-specific serostatus as
preliminary assay to screen and monitor the relevant T-cell immunity and showed antigen-specific T cells to be present
in 73% of ADV-seropositive donors [33].
JC POLYOMAVIRUS: SIGNIFICANCE OF SERO-STATUS IN THE MANAGEMENT OF A PERSISTENT
VIRUS
In the field of viral persistence, it is nowadays ascertained that the persistent infection caused by JC polyomavirus
(JCV) and its reactivation are prerequisites for the onset of the progressive multifocal leukoencephalopathy (PML),
observed in immunocompromised subjects [34]. Gorelik and colleagues described a JCV-specific higher-affinity ELISA
performed for retrospectively assessing the JCV serostatus before the immunosuppressive therapy in multiple sclerosis
patients, and to achieve a PML risk stratification. The authors detected anti-JCV antibodies in 100% of serum samples
collected prior to PML diagnosis [35]. They also detected JCV DNA in urine to identify infected individuals and to
establish  the  positive  reference sera.  Moreover,  JCV as  well  shows important  genomic and phenotypic  plurality  of
strains.  Particularly,  a  set  of  mutations,  deletions  and  duplication  verifying  in  noncoding  control  region  (NCCR)
sequence of JCV genome was found as modifying the archetype polyomavirus JC and allowing neurovirulence, i.e., the
virus entrance into human central nervous system, a preliminary condition for PML onset [36]. This feature does not
make vain a possible application of serology for the prevention of PML. On the contrary, it led to a project aimed to
restrict the identification of high-risk subjects to those bearing JCV DNA rearrangement [37]. The diseases caused by
the reactivation of JCV and HAdV due to immunosuppressive therapies, or due to any immunodeficiency status, share
the  lack  of  effective  therapies  and  the  great  necessity  to  identify  subjects  at  risk.  The  management  of
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immunosuppressive  protocols  and  pre-transplant  screening  cannot  include  the  evaluation  of  anti-polyomavirus
serostatus, since commercial routine assays to perform standardized measures are not nowadays available. Serological
assays detecting HAdV-antibodies, instead, are suitable in microbiology laboratories for achieving diagnosis for acute
and symptomatic infections in immune competent subjects [2, 38].
CONCLUSION
In the case of immunodeficiency planned for conditioning regimens or for therapeutic protocols, any effort have to
be supported to avoid as much as possible primary infections with latent and persistent viruses and microorganisms, and
their reactivation, or to be at least strictly aware of the underlying risk resulting from the treatment. The same authors
who propose the PCR-based surveillance of  HAdV infection are not  sure whether  this  method is  of  benefit  for  the
patients. However, they consider direct molecular assay as an opportunity they recommend not to waste [16, 23]. The
management of immunosuppressive therapies performed without using every available tool to avoid or reduce the risk
of consequent infections, diseases and death, could be an extreme responsibility.
To  conclude,  the  pre-transplant  screening  should  include  the  evaluation  of  latent  HAdV infections,  performing
serological tests in donor and recipient, similar to the screening aimed at preventing cytomegalovirus infections. It is
important  to  remind  that  the  serological  CMV  screening  is  performed  in  spite  of  the  existence  of  established  and
effective therapies. This screening currently represents a necessary condition, even if not sufficient, to prevent and to
manage the onset of CMV infection in immunocompromised patients [11, 12]. It  allows the protective matching of
donors  and  recipients,  avoiding  organ  transplantation  from  a  seropositive  donor  to  a  seronegative  recipient,  the
discovery of subjects at risk to carefully survey, the consequent preemptive therapy and active or passive immunization
to prevent post-transplant CMV infections.
Improving  the  pre-transplant  screening  with  serostatus  towards  HAdV obviously  would  not  exclude  the  use  of
molecular assay for early surveillance, which most clinicians believe as the best method to manage the consequences of
graft related immunodeficiency. Indeed, in some setting, molecular assays are not only performed on blood, to discover
disseminate infections, but also on accessible tracts [18, 21]. This procedure can be useful especially in the contest of
solid organ transplantation, where HAdV infections firstly involve the graft and are not early revealed by blood PCR
surveillance. Moreover, prior to transplant, the detection of HAdV DNA on accessible tracts of recipients, along with
that on graft’s tissue, could be performed to preliminarily know the risk of reactivation and to avoid or minimize the
risk  of  primary  infection.  The  HAdV  serological  screening  would  not  imply  any  procedural  waste  or  danger  or
significant increase of the coasts, representing just a complementary test.
The epidemiological data emerging from a pre-transplant HAdV serological screening could be useful for enhancing
the knowledge of adenoviral pathogenesis, nowadays incomplete on several aspects. As already mentioned, the most
unclear  and  important  query  concerns  the  true  responsibility  by  the  primary  infection  via  the  graft  and  by  the
reactivation of pre-existing viruses in the onset of the infection in the immune-compromised host [9]. The interesting
association joining the graft versus host disease (GvHD) and CMV reactivation is recently found for HAdV as well [39,
40]. On the contrary, in children with severe steroid-refractory acute GvHD treated with mesenchymal stromal cells,
HAdV but not CMV infection was associated with decreased survival [41]. Therefore, the knowledge on connections
between HAdV and not  infectious  complications  of  transplant  procedures,  such as  allograft  rejection and loss,  and
GvHD, could benefit from acquisition of new serological data [5, 7].
The specific associations between adenovirus species or individual types and single diseases is also not clear [2, 4].
New serological data can add information on the most frequent serotypes, the relative neutralizing antibodies and their
possible cross-protective activity, on serotypes connected with graft’s complications, with different localizations and
with high case fatality.
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